Upcoming Seminar to Discuss Advantages and Opportunities of ADRs and OTCQX Trading

MZ Group, BNY Mellon, OTC Markets Group, and White & Case are hosting a special seminar next week to help executives and IR professionals learn more about the fastest growing marketplace for ADRs in the U.S. and why the largest and best international companies are choosing OTCQB for their U.S. investors. Taking place in Sao Paulo on December 11, 2012, the Globalize Your Outreach seminar will discuss the various benefits and requirements of establishing ADRs (American Depositary Receipts) for access to international investors.

Agenda
08:30 am – Registration and Coffee Break
09:00 am – Introduction by MZ Group
09:20 am – The Value of the BNY Mellon ADR
09:40 am – The OTCQB as your trading platform
10:00 am – Legal Requirements and Regulations
10:20 am – Q&A Session
10:45 am – Closing

In a press release from earlier this week, MZ North America’s John Mattio explained the importance of the information that will be presented.

“Investors are usually attracted to companies that follow clear quantitative standards and disclose their documents to the international market with the highest standards of quality,” he stated. ”By combining ADRs and the OTCQX, companies can have access to U.S. and global investors without the additional regulatory costs involved in listing on a conventional U.S. stock exchange. It can be a long-term solution for the company’s needs or the first step towards listing on the NYSE, AMEX or NASDAQ.”

The event has a limited number of seats. To register for this seminar, visit http://dtg.fm/globalize-your-outreach-rsvp

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Cardium Therapeutics, Inc. (CXM) Targets the Healthy Lifestyle Market Through To Go Brands

In October of 2012, Cardium Therapeutics, a health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative health products, acquired To Go Brands, a developer of easy-to-use nutraceuticals. To Go Brands products are known for being 100% natural, organic, and antioxidant rich, but in convenient forms that can be used in the home or on the run, such as drink mixes and capsule-based dietary supplements.

The acquisition was a natural one for Cardium, representing with its dynamic brands an important portal to the wide-ranging health community. To Go Brands, through its developing Web presence and social networking, is increasingly positioning itself as an information source as well as a product source. The company uses Facebook, Twitter, Pinterest, and other social media to actively connect with the rapidly growing market of people seeking the healthy lifestyle.

An example is the company’s ongoing use of unique and fun health-oriented recipes that represent a natural draw to health conscious consumers. Examples include Sweet and Simple Apple Oatmeal, Green & Icy! Non-dairy Ice Cream, Pacific Northwest Smoothie, Key Lime Delight, Healthy To Go Breakfast, Super Fruit ‘n Flax Smoothie, and various creative drinks.

A recent sampling of the To Go Brands blog covers everything healthy:

• Holiday Weight Loss Guide
• Candy to Avoid
• Why Whey Protein
• Green Coffee Bean- The New Magic Bean
• Losing weight naturally!
• Omega To Go® eliminates the “Middle Fish”
• What is ACAI?
• 7 Important Nutrients and How They Benefit the Body
• Is Stress Causing Your Weight Gain?

For additional information, visit www.CardiumTHX.com and www.ToGoBrands.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

SciClone Pharmaceuticals, Inc. (SCLN) New ZADAXIN Anti-Counterfeiting Label Receives Prestigious Industry Award

SciClone Pharmaceuticals announced that in the annual competition sponsored by the Tag and Label Manufacturers Institute (TLMI), its newly created anti-counterfeiting Pharma-Comb Void label for ZADAXIN has won the prestigious “Innovator Award.”

Created for SciClone by Schreiner MediPharm, a developer and manufacturer of pharmaceutical specialty labels based in Germany, the ZADAXIN label has been designed based on an innovative multipart concept to ensure product safety and security, as well as to counteract the illegal practice of refilling previously used medicine vials.

The serious problem of drug counterfeiting is a challenge facing the pharmaceutical industry, public health and regulatory authorities throughout the world. This problem is also a threat to patient safety, compromising the supply and efficacy of medical interventions as well as damaging the commercial viability of important drug therapies. Committed to ensuring patient safety and security for all its marketed products, SciClone intends to continue implementing an aggressive anti-counterfeiting strategy for ZADAXIN, working collaboratively with agencies and health authorities to fight the crime of illegal medication trafficking.

During its initial use, the ZADAXIN Pharma-Comb Void label is designed to be functionally destroyed. The inscriptions “Opened” and “Used” appear in two indicator fields when the label’s tear strip – which also encircles the closure cap – is removed. This design is intended to make it virtually impossible to reuse a glass container with an original label without the fraudulence being detected. The company believes that its Pharma-Comb Void label overcomes the limitations of conventional vials, which can be filled a second time and sold, undetected, as originals – even when equipped with overt security features like holograms or color-shifting inks. The new ZADAXIN label has been created to counteract this practice; it also offers a valuable-added benefit for healthcare professionals, which is that a detachable part is released when the label is opened, serving to mark the syringe accordingly.

China-focused but based in the United States, SciClone Pharmaceuticals is a specialty pharmaceutical company with a portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory and central nervous system disorders. The company’s ZADAXIN (thymalfasin) has been approved in more than 30 countries and can be used to treat hepatitis B, hepatitis C and certain cancers, as well being used as a vaccine adjuvant, according to the legal regulatory approvals. In addition to ZADAXIN, SciClone also markets around 14 products in China, mostly partnered, including Depakine, Tritace, Stilnox (marketed as Ambien in the U.S.) and Aggrastat. The company is additionally pursuing the registration of various other therapeutic products in China.

For more information, visit the company’s Web site at www.sciclone.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Kratos (KTOS) Provides Target Drones for First Patriot Missile Firing for Hellenic Air Defense Exercise at NATO Missile Firing Installation

Kratos Defense & Security Solutions, Inc., a prominent provider of National Security Solutions, announced that its subsidiary, Composite Engineering Inc. (CEI), supported the Hellenic Air Defense Forces’ live fire exercises for the Patriot Weapon System on November 17, 2012, at the NATO Missile Firing Installation on the Greek Isle of Crete. Specifically, Kratos’ internationally utilized Firejet aerial target drone system served as a simulated advanced, aerial threat against the Joint Forces. The Firejet system was designed and produced by CEI.

During the exercises, Kratos’ Firjet target drone flew a precise and predetermined flight path, mimicking a possible real-world threat, and was tracked, engaged, and fired upon successfully by a Patriot Weapon System. In a letter of appreciation received by Kratos CEI and their local partner, ALTUS LSA, the NAMFI Commander said that “perfect cooperation and communication was achieved between all involved parties, a fact that illustrated that the companies CEI and ALTUS LSA are manned with highly trained and competent personnel and also the service provision on their behalf are of high standards.”

Designed and manufactured exclusively by Kratos’ CEI, the Firejet target system is the third generation of the company’s cutting edge, high-speed aerial target drone system. CEI is currently a supplier of high performance aerial target drones to the United States Air Force and United States Navy, and has expanded its services to including supporting missile-firing exercises with its impressive suite of aerial target systems.

Richard Selvaggio, President of Kratos’ Unmanned Systems Solution Division, said, “I am extremely proud of our CEI team and our FireJet aerial target drone systems performance in providing advanced threat representations in support of some of the world’s most advanced air and missile defense systems at one the world’s premier missile firing ranges. Kratos’ FireJet System is a key element in our strategy to be the premier global provider of aerial targets, which represent some of the the most lethal threats facing the United States and our Allies Armed Forces throughout the world. Kratos Target Systems, including Kratos Aegis Readiness Assessment Vehicle (ARAV), are supporting many of the most advanced air and ballistic missile defense systems deployed today.”

For further information, please visit www.KratosDefense.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

AK Steel Holding Corporation (AKS) Video Chart for Wednesday, December 5, 2012

AKS has bounced from 52-week lows of $3.42 and is establishing a new support level at $3.85. Indicators of trend and momentum are shifting and hinting that the upward pressure will continue. Significant resistance doesn’t enter
the chart until the area of $4.70.

To view the video chart, visit the following link: http://www.missionir.com/videos.html

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

FuelCell Energy, Inc. (FCEL) Reports Sale of a Power Plant to Be Installed at London Office Tower

FuelCell Energy is a global leader in the design, manufacture, operation, and service of ultra-clean, efficient, and reliable fuel cell power plants. The company’s power plants are generating clean power at more than 50 sites around the globe. It has approximately 300 megawatts of power generation capacity installed worldwide or in backlog.

The company announced today that its German subsidiary, FuelCell Energy Solutions GmbH (FCES), will manufacture and install a stationary fuel cell power plant at the 20 Fenchurch office development in London, England, being built by the Canary Wharf Group. The ultra-clean and efficient power plant will facilitate clean air permitting and support London’s carbon reduction targets. FCES will also operate and maintain the power plant.

The quiet operation and virtual lack of pollutants from fuel cells is ideally suited for populated areas such as London. The power generation process of the fuel cell uses an electrochemical reaction rather than combustion of hydrocarbons, which very effectively converts fuel into clean electricity and heat suitable for generating steam. The electrochemical power generation process is also quiet and free of vibrations.

Fuel cells of this type can generate up to 90% efficiency. The heat for this particular fuel cell installation will be used for facility heating and cooling, resulting in an estimated overall efficiency above 85%. The power plant will be installed in 2013 and be ready for the building completion in 2014.

For additional information about FuelCell Energy, visit www.fuelcellenergy.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Biostar Pharmaceuticals, Inc. (BSPM) Signs $8 Million Agreement to Supply Xijing Military Hospital with 16 New Drugs

Biostar Pharmaceuticals, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products for a variety of diseases and conditions in China, today announced that the company, on November 26, 2012, signed another one-year agreement with Xijing Military Hospital valued at approximately $8 million. The agreement requires that Biostar manufacture and supply Xijing Military Hospital with 16 new drugs used to treat an array of diseases such as pharyngitis, nasopharynx, gastroenteropathy, nephropathy, asthma, hyperplasia of mammary glands, dermatosis, gynecological diseases, etc.

The material terms of this agreement are comparable to the previous two one-year agreements Biostar signed with the same hospital back in September and October 2012, valued at $3.6 million and $3.0 million, respectively. The addition of this new agreement brings Biostar’s sum to 24 drugs which the company currently manufactures for Xijing Military Hospital (10 granules, 13 capsules, and one powder drug) totaling a combined worth of $14.6 million.

“We are pleased to have signed another drug manufacturing contract with Xijing Military Hospital as we continue to expand our drug portfolio with high quality products that are manufactured specifically for the needs of this hospital,” said Ronghua Wang, Biostar’s Chief Executive Officer and Chairman. “The signing of these agreements is a result of our hard work to quickly complete experimental tests, trial production, and pass manufacturing technology and quality inspections. These types of contracts have the potential to generate substantial revenues, have very low sales expenses and a much shorter sales cycle.”

Mr. Wang commented further, stating, “These agreements mark the initial step of our strategic partnership with The Fourth Military Medical University (‘FMMU’), one of China’s most prestigious military medical universities and research centers. As previously announced, we are working to become a strategic partner of FMMU in the fields of research and product development and also to become a production base for manufacturing drugs specifically for the needs of China’s military.”

For more information on Biostar Pharmaceuticals, visit www.biostarpharmaceuticals.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html